NIH Return-On-Investment Report Will Be Subject Of Senate Hearing This Fall
Executive Summary
The Senate Commerce/Science Subcommittee will hold hearings this fall on the return to taxpayers from research funded by the National Institutes of Health.
You may also be interested in...
Closing The Books On Taxol: GAO Report Fuels Sen. Wyden’s Pricing Push
NIH should consider the cost of new therapies to Medicare when negotiating technology transfers for taxpayer-funded research, Sen. Ron Wyden (D-Ore.) maintained in response to a June 4 1GAO report on the National Institutes of Health's collaboration with Bristol for the oncologic agent Taxol
Closing The Books On Taxol: GAO Report Fuels Sen. Wyden’s Pricing Push
NIH should consider the cost of new therapies to Medicare when negotiating technology transfers for taxpayer-funded research, Sen. Ron Wyden (D-Ore.) maintained in response to a June 4 1GAO report on the National Institutes of Health's collaboration with Bristol for the oncologic agent Taxol
NIH-funded research
Senate Commerce/Science Subcommittee Chairman Ron Wyden (R-Ore.) no longer plans hearings or legislation to address the return to taxpayers from research funded by the National Institutes of Health. Wyden met Oct. 10 with reps from NIH, the pharmaceutical industry and research institutions. Wyden is understood to be satisfied by NIH's plan to begin implementation of a web-based database of approved drugs that use technology funded by NIH and to use standardized language to simplify reporting requirements by Jan. 1 (1"The Pink Sheet" Aug. 27, p. 3)